{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:33:50Z","timestamp":1792704830931,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1888,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1124\/jpet.119.261099","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T22:39:02Z","timestamp":1565649542000},"page":"231-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models"],"prefix":"10.1016","volume":"371","author":[{"given":"Joseph","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bobardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udayan","family":"Chatterji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Trepanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gallay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daren R.","family":"Ure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.261099_bib1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.yjmcc.2014.09.026","article-title":"Cyclophilin D and myocardial ischemia-reperfusion injury: a fresh perspective","volume":"78","author":"Alam","year":"2015","journal-title":"J Mol Cell Cardiol"},{"key":"10.1124\/jpet.119.261099_bib2","doi-asserted-by":"crossref","first-page":"E1723","DOI":"10.3390\/ijms20071723","article-title":"The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma","volume":"20","author":"Baglieri","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.119.261099_bib3","unstructured":"BC Transplant Provincial Health Services Authority (2019) BC clinical guidelines for transplant medications"},{"key":"10.1124\/jpet.119.261099_bib4","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1038\/onc.2016.42","article-title":"Cyclophilin D counteracts P53-mediated growth arrest and promotes Ras tumorigenesis","volume":"35","author":"Bigi","year":"2016","journal-title":"Oncogene"},{"key":"10.1124\/jpet.119.261099_bib5","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/cdd.2016.45","article-title":"Proline isomerisation as a novel regulatory mechanism for p38MAPK activation and functions","volume":"23","author":"Brichkina","year":"2016","journal-title":"Cell Death Differ"},{"key":"10.1124\/jpet.119.261099_bib6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.tips.2018.11.004","article-title":"Mitochondrial permeability transition: a molecular lesion with multiple drug targets","volume":"40","author":"Briston","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.119.261099_bib7","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/jvh.12360","article-title":"Alisporivir with peginterferon\/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial","volume":"22","author":"Buti","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1124\/jpet.119.261099_bib8","doi-asserted-by":"crossref","first-page":"e1004465","DOI":"10.1371\/journal.pgen.1004465","article-title":"Abnormal type I collagen post-translational modification and crosslinking in a cyclophilin B KO mouse model of recessive osteogenesis imperfecta","volume":"10","author":"Cabral","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1124\/jpet.119.261099_bib9","doi-asserted-by":"crossref","first-page":"e0127668","DOI":"10.1371\/journal.pone.0127668","article-title":"Cyclophilin J is a novel peptidyl-prolyl isomerase and target for repressing the growth of hepatocellular carcinoma","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.261099_bib10","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1158\/0008-5472.CAN-13-0771","article-title":"Cyclophilin B supports Myc and mutant p53-dependent survival of glioblastoma multiforme cells","volume":"74","author":"Choi","year":"2014","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.119.261099_bib11","doi-asserted-by":"crossref","first-page":"e1000750","DOI":"10.1371\/journal.pgen.1000750","article-title":"Severe osteogenesis imperfecta in cyclophilin B-deficient mice","volume":"5","author":"Choi","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1124\/jpet.119.261099_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/path.5107","article-title":"Cyclophilin B induces chemoresistance by degrading wild-type p53 via interaction with MDM2 in colorectal cancer","volume":"246","author":"Choi","year":"2018","journal-title":"J Pathol"},{"key":"10.1124\/jpet.119.261099_bib13","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1158\/1078-0432.CCR-13-1059","article-title":"Molecular pathways: connecting fibrosis and solid tumor metastasis","volume":"20","author":"Cox","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.119.261099_bib14","doi-asserted-by":"crossref","first-page":"e1000439","DOI":"10.1371\/journal.pbio.1000439","article-title":"Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases","volume":"8","author":"Davis","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1124\/jpet.119.261099_bib15","first-page":"1","article-title":"Cyclophilin A: a key factor in virus replication and potential target for anti-viral therapy","volume":"21","author":"Dawar","year":"2017","journal-title":"Curr Issues Mol Biol"},{"key":"10.1124\/jpet.119.261099_bib16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1189\/jlb.3RU1116-477R","article-title":"Updates in understanding the role of cyclophilin A in leukocyte chemotaxis","volume":"101","author":"Dawar","year":"2017","journal-title":"J Leukoc Biol"},{"key":"10.1124\/jpet.119.261099_bib17","doi-asserted-by":"crossref","first-page":"9622","DOI":"10.1021\/acs.jmedchem.6b00411","article-title":"Peptidyl-proline isomerases (PPIases): targets for natural products and natural product-inspired compounds","volume":"59","author":"Dunyak","year":"2016","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.261099_bib18","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2011-12-398438","article-title":"Intracellular cyclophilin A is an important Ca(2+) regulator in platelets and critically involved in arterial thrombus formation","volume":"120","author":"Elvers","year":"2012","journal-title":"Blood"},{"key":"10.1124\/jpet.119.261099_bib19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/337476a0","article-title":"Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins","volume":"337","author":"Fischer","year":"1989","journal-title":"Nature"},{"key":"10.1124\/jpet.119.261099_bib20","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1021\/jm500862r","article-title":"Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition","volume":"57","author":"Fu","year":"2014","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.261099_bib21","doi-asserted-by":"crossref","first-page":"e0134707","DOI":"10.1371\/journal.pone.0134707","article-title":"The novel cyclophilin inhibitor CPI-431-32 concurrently blocks HCV and HIV-1 infections via a similar mechanism of action","volume":"10","author":"Gallay","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.261099_bib22","doi-asserted-by":"crossref","first-page":"e0217433","DOI":"10.1371\/journal.pone.0217433","article-title":"The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice","volume":"14","author":"Gallay","year":"2019","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.261099_bib23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/10409238.2016.1269716","article-title":"Molecular insights into prolyl and lysyl hydroxylation of fibrillar collagens in health and disease","volume":"52","author":"Gjaltema","year":"2017","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1124\/jpet.119.261099_bib24","doi-asserted-by":"crossref","first-page":"22378","DOI":"10.1038\/srep22378","article-title":"Cyclophilin A (CypA) plays dual roles in regulation of bone anabolism and resorption","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.119.261099_bib25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/1759-7714.12548","article-title":"Cyclophilin A promotes non-small cell lung cancer metastasis via p38 MAPK","volume":"9","author":"Guo","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1124\/jpet.119.261099_bib26","doi-asserted-by":"crossref","first-page":"e0124606","DOI":"10.1371\/journal.pone.0124606","article-title":"The novel extracellular cyclophilin A (CyPA)-inhibitor MM284 reduces myocardial inflammation and remodeling in a mouse model of troponin I-induced myocarditis","volume":"10","author":"Heinzmann","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.261099_bib27","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/1440-1681.12881","article-title":"Cyclophilin D promotes tubular cell damage and the development of interstitial fibrosis in the obstructed kidney","volume":"45","author":"Hou","year":"2018","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1124\/jpet.119.261099_bib28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jneuroim.2017.07.016","article-title":"Cyclophilin inhibitor NIM811 ameliorates experimental allergic encephalomyelitis","volume":"311","author":"Huang","year":"2017","journal-title":"J Neuroimmunol"},{"key":"10.1124\/jpet.119.261099_bib29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2119\/molmed.2015.00076","article-title":"Targeting extracellular cyclophilins ameliorates disease progression in experimental biliary atresia","volume":"21","author":"Iordanskaia","year":"2015","journal-title":"Mol Med"},{"key":"10.1124\/jpet.119.261099_bib30","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/hep.24539","article-title":"Role of cyclophilin B in tumorigenesis and cisplatin resistance in hepatocellular carcinoma in humans","volume":"54","author":"Kim","year":"2011","journal-title":"Hepatology"},{"key":"10.1124\/jpet.119.261099_bib31","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1021\/bi00239a007","article-title":"Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay","volume":"30","author":"Kofron","year":"1991","journal-title":"Biochemistry"},{"key":"10.1124\/jpet.119.261099_bib32","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1478-3231.2007.01560.x","article-title":"NIM811, a nonimmunosuppressive cyclosporine analogue, suppresses collagen production and enhances collagenase activity in hepatic stellate cells","volume":"27","author":"Kohjima","year":"2007","journal-title":"Liver Int"},{"key":"10.1124\/jpet.119.261099_bib33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.119.261099_bib34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2174\/1874467208666150519115443","article-title":"Cyclophilin function in cancer; lessons from virus replication","volume":"9","author":"Lavin","year":"2015","journal-title":"Curr Mol Pharmacol"},{"key":"10.1124\/jpet.119.261099_bib35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/jat\/15.3.110","article-title":"Concentrations of cyclosporin A and its metabolites in human tissues postmortem","volume":"15","author":"Lensmeyer","year":"1991","journal-title":"J Anal Toxicol"},{"key":"10.1124\/jpet.119.261099_bib36","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/ajt.12620","article-title":"REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C","volume":"14","author":"Levy","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1124\/jpet.119.261099_bib37","first-page":"847","article-title":"The protective effect of cyclosporine against cirrhotic alteration of the liver","volume":"110","author":"Lie","year":"1991","journal-title":"Surgery"},{"key":"10.1124\/jpet.119.261099_bib38","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1038\/onc.2017.41","article-title":"Selective targeting p53WT lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA","volume":"36","author":"Lu","year":"2017","journal-title":"Oncogene"},{"key":"10.1124\/jpet.119.261099_bib39","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1039\/C1MD00227A","article-title":"Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection","volume":"3","author":"Moss","year":"2012","journal-title":"MedChemComm"},{"key":"10.1124\/jpet.119.261099_bib40","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1016\/j.transproceed.2005.10.104","article-title":"Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells","volume":"37","author":"Nakamuta","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1124\/jpet.119.261099_bib41","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2014.07.008","article-title":"Cyclophilin inhibition as potential therapy for liver diseases","volume":"61","author":"Naoumov","year":"2014","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.119.261099_bib42","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.1038\/cddis.2013.410","article-title":"Cyclophilin A: a key player for human disease","volume":"4","author":"Nigro","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1124\/jpet.119.261099_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1084\/jem.20101174","article-title":"Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice","volume":"208","author":"Nigro","year":"2011","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.119.261099_bib44","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s13277-014-2691-5","article-title":"Secreted cyclophilin A mediates G1\/S phase transition of cholangiocarcinoma cells via CD147\/ERK1\/2 pathway","volume":"36","author":"Obchoei","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1124\/jpet.119.261099_bib45","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hep.27960","article-title":"Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"Hepatology"},{"key":"10.1124\/jpet.119.261099_bib46","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/biom8040176","article-title":"Cyclophilin D, somehow a master regulator of mitochondrial function","volume":"8","author":"Porter","year":"2018","journal-title":"Biomolecules"},{"key":"10.1124\/jpet.119.261099_bib47","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1124\/jpet.108.143578","article-title":"NIM811 (N-methyl-4-isoleucine cyclosporine), a mitochondrial permeability transition inhibitor, attenuates cholestatic liver injury but not fibrosis in mice","volume":"327","author":"Rehman","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.261099_bib48","first-page":"183","article-title":"The effects of SCY-635, a nonimmunosuppressive cyclosporine analog on stellate cell proliferation, collagen synthesis, TIMP-1 and collagenase production","volume":"52","author":"Scorneaux","year":"2010","journal-title":"Hepatology"},{"key":"10.1124\/jpet.119.261099_bib49","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.yjmcc.2012.03.004","article-title":"Cyclophilin A affects inflammation, virus elimination and myocardial fibrosis in coxsackievirus B3-induced myocarditis","volume":"53","author":"Seizer","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"10.1124\/jpet.119.261099_bib50","doi-asserted-by":"crossref","first-page":"e0155709","DOI":"10.1371\/journal.pone.0155709","article-title":"Cyclophilin D knock-out mice show enhanced resistance to osteoporosis and to metabolic changes observed in aging bone","volume":"11","author":"Shum","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.261099_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20071745","article-title":"Recent insight into the role of fibrosis in nonalcoholic steatohepatitis-related hepatocellular carcinoma","volume":"20","author":"Sircana","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.119.261099_bib52","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4103\/1673-5374.235218","article-title":"Targeting the mitochondrial permeability transition pore in traumatic central nervous system injury","volume":"13","author":"Springer","year":"2018","journal-title":"Neural Regen Res"},{"key":"10.1124\/jpet.119.261099_bib53","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/14656566.2018.1560424","article-title":"Efficacy and safety of alisporivir for the treatment of hepatitis C infection","volume":"20","author":"Stanciu","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/jpet.119.261099_bib54","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1021\/jm500223x","article-title":"From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds","volume":"57","author":"Sweeney","year":"2014","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.261099_bib55","doi-asserted-by":"crossref","first-page":"9501","DOI":"10.1074\/jbc.M115.699470","article-title":"Cyclophilin-B modulates collagen cross-linking by differentially affecting lysine hydroxylation in the helical and telopeptidyl domains of tendon type I collagen","volume":"291","author":"Terajima","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.119.261099_bib56","first-page":"e118","article-title":"Functions of cyclophilin A in atherosclerosis","volume":"18","author":"Tian-Tian","year":"2013","journal-title":"Exp Clin Cardiol"},{"key":"10.1124\/jpet.119.261099_bib57","doi-asserted-by":"crossref","first-page":"335s","DOI":"10.18433\/jpps30245","article-title":"Development, characterization, and pharmacokinetic evaluation of a crv431 loaded self-microemulsifying drug delivery system","volume":"21","author":"Trepanier","year":"2018","journal-title":"J Pharm Pharm Sci"},{"key":"10.1124\/jpet.119.261099_bib58","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0090-9556(25)06712-1","article-title":"Tissue distribution, disposition, and metabolism of cyclosporine in rats","volume":"15","author":"Wagner","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.119.261099_bib59","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1440-1746.2010.06406.x","article-title":"N-methyl-4-isoleucine cyclosporine attenuates CCl -induced liver fibrosis in rats by interacting with cyclophilin B and D","volume":"26","author":"Wang","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1124\/jpet.119.261099_bib60","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.29788","article-title":"Cyclophilin D deficiency attenuates mitochondrial perturbation and ameliorates hepatic steatosis","volume":"68","author":"Wang","year":"2018","journal-title":"Hepatology"},{"key":"10.1124\/jpet.119.261099_bib61","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.117.310661","article-title":"Extracellular and intracellular cyclophilin A, native and post-translationally modified, show diverse and specific pathological roles in diseases","volume":"38","author":"Xue","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/jpet.119.261099_bib62","doi-asserted-by":"crossref","first-page":"10342","DOI":"10.3390\/molecules200610342","article-title":"Discovery of novel small molecule anti-HCV agents via the CypA inhibitory mechanism using o-acylation-directed lead optimization","volume":"20","author":"Yan","year":"2015","journal-title":"Molecules"},{"key":"10.1124\/jpet.119.261099_bib63","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2249.2010.04115.x","article-title":"Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics","volume":"160","author":"Yurchenko","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1124\/jpet.119.261099_bib64","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/apt.13342","article-title":"Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naive patients with chronic HCV genotype 1 infection (ESSENTIAL II)","volume":"42","author":"Zeuzem","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.119.261099_bib65","doi-asserted-by":"crossref","first-page":"e92824","DOI":"10.1371\/journal.pone.0092824","article-title":"CypA, a gene downstream of HIF-1\u03b1, promotes the development of PDAC","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.261099_bib66","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11010-011-0909-z","article-title":"Cyclophilin A promotes human hepatocellular carcinoma cell metastasis via regulation of MMP3 and MMP9","volume":"357","author":"Zhang","year":"2011","journal-title":"Mol Cell Biochem"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524268981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524268981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.261099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:58:34Z","timestamp":1739973514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524268981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0022356524268981"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.261099","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.261099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}